Cargando…
The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
Although the cardiovascular (CV) polypill concept is not new and several guidelines state that a CV polypill should be considered an integral part of a comprehensive CV disease (CVD) prevention strategy, there are still some barriers to its implementation in the real-world setting, mainly in seconda...
Autores principales: | Grigorian-Shamagian, Lilian, Coca, Antonio, Morais, Joao, Perez-Martinez, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433542/ https://www.ncbi.nlm.nih.gov/pubmed/37587509 http://dx.doi.org/10.1186/s12919-023-00268-9 |
Ejemplares similares
-
Correction: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2023) -
Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
por: Grigorian-Shamagian, Lilian, et al.
Publicado: (2021) -
Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
por: Aguiar, Carlos, et al.
Publicado: (2022) -
The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico
por: Gómez-Álvarez, Enrique, et al.
Publicado: (2020) -
Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option
por: Castagnari, Aldo
Publicado: (2008)